Literature DB >> 25696757

Safety of statins in the new millennium.

J W Jukema, P J Lansberg.   

Abstract

Looking at the world today and six months ago in retrospect, it becomes clear that things have changed dramatically. Not only are global economic forecasts in turmoil, other certainties have also been proven to be not as steadfast as we had hoped and expected. Safety in the world has gained a different perspective since the assault on the twin towers of the World Trade Centre in New York and the Pentagon. The safety of medicine and especially statins has also become an issue since the withdrawal of cerivastatin because of its possible association with an increased rate of rhabdomyolysis under certain circumstances.

Entities:  

Keywords:  HMG-CoA reductase inhibitors; lipid-lowering drugs; rhabdomyolysis; safety; statins

Year:  2001        PMID: 25696757      PMCID: PMC2499648     

Source DB:  PubMed          Journal:  Neth Heart J        ISSN: 1568-5888            Impact factor:   2.380


  4 in total

Review 1.  Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust.

Authors:  M H Davidson
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.

Authors:  D K Murdock; A K Murdock; R W Murdock; K J Olson; A M Frane; M E Kersten; D M Joyce; S E Gantner
Journal:  Am Heart J       Date:  1999-07       Impact factor: 4.749

3.  Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy.

Authors:  L R Pierce; D K Wysowski; T P Gross
Journal:  JAMA       Date:  1990-07-04       Impact factor: 56.272

4.  Emerging tobacco hazards in China: 1. Retrospective proportional mortality study of one million deaths.

Authors:  B Q Liu; R Peto; Z M Chen; J Boreham; Y P Wu; J Y Li; T C Campbell; J S Chen
Journal:  BMJ       Date:  1998-11-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.